In a groundbreaking advancement for breast cancer treatment, a new DNA test could allow millions of patients to bypass the often-grueling regimen of chemotherapy. An extensive international study led by University College London (UCL) demonstrates that this novel approach may significantly reduce the side effects suffered by many who are diagnosed.
The trial, which involved more than 4,000 newly diagnosed patients aged over 40 across countries including the UK, Norway, Sweden, Australia, New Zealand, and Thailand, revealed that approximately two-thirds of participants could effectively avoid chemotherapy. Instead, they could be managed with hormone therapy alone.
Standard chemotherapy, while beneficial for some, is notorious for its debilitating side effects such as fatigue, nausea, hair loss, weakened immunity, and fertility complications. Consequently, the prospect of reducing or eliminating such an ordeal offers newfound hope for those facing breast cancer.
The researchers utilized a sophisticated gene test called Prosigna, which assesses the activity of 50 specific genes involved in breast cancer proliferation. By gauging this genetic activity, clinicians could calculate a patient’s risk of cancer recurrence. Remarkably, those who received a low-risk score—representing around two-thirds of the trial cohort—did not require chemotherapy, attaining a five-year survival rate of 93.7%, closely comparable to the 94.9% survival rate of patients who underwent chemotherapy.
Traditionally, breast cancer management starts with surgery to excise tumors, followed by chemotherapy to mitigate the chance of recurrence. However, concerns have mounted regarding the actual benefit of chemotherapy for many diagnosed with early-stage breast cancer.
UCL estimates that based on these findings, over 5,000 patients within the National Health Service (NHS) in the UK could avoid chemotherapy each year. Among the participants, Karen Bonham from Cardiff expressed profound relief at being able to avoid chemotherapy, stating, "It feels like Christmas." The 64-year-old underwent eight years of radiotherapy and hormone therapy after her Prosigna test indicated she would be better off without chemotherapy.
"Cancer diagnosis and treatment can be shocking and propel you into a world of uncertainty," Bonham added, highlighting the urgency that such a diagnosis creates in realigning life priorities.
The pivotal results are set to be showcased at the American Society of Clinical Oncology's annual meeting in Chicago this weekend, underscoring their importance on the global stage. Professor Rob Stein, the chief investigator and UCL Cancer Institute's professor of breast oncology, remarked, "These results signify a monumental step towards personalizing cancer treatment. By integrating tumour biology into clinical decision-making, we are moving beyond traditional frameworks to tailor therapies to individual patient needs. This means many patients can avoid the physical and emotional burdens of chemotherapy. Moreover, it allows for a more judicious allocation of healthcare resources on a systemic level."
While the study predominantly focused on patients over 40, researchers caution that further investigations are needed to determine if these findings can be generalized to younger patients, a topic that remains several years away from resolution.
For now, this innovative DNA test stands as a beacon of hope for millions navigating the daunting landscape of breast cancer treatment.
Source: BBC News - Health
